Chugai Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chugai Pharmaceutical Co., Ltd.
Eiger attributes the change in status of the EU marketing authorization application for lonafarnib to the need for an inspection and the ongoing coronavirus pandemic.
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
With the global pandemic leading to a big rise in mental health issues, could have a role to play. In Vivo explores transcranial magnetic stimulation systems that are being used to treat severe anxiety and depression, among other indications. As well as the skyrocketing use of telehealth, apps and light therapy for mental health indications.
The IPO is expected to raise $166m to support R&D of new arrhythmia mapping and ablation technologies and expand commercial operations.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Chugai Pharma Europe
- Chugai Pharma Taiwan Ltd.
- C&C Research Laboratories